title: [Pharmacological and clinical profiles of the DPP-4 inhibitor linagliptin (Trazenta)].
authors.affiliation: tsuyoshi.ohmura@boehringer-ingelheim.com
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Ohmura
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Hayashi
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Encinas
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D005951:Glucose Tolerance Test; D006801:Humans; D007004:Hypoglycemic Agents; D000069476:Linagliptin; D011687:Purines / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D011799:Quinazolines / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D051437:Renal Insufficiency / Q000378:metabolism
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D011687:Purines; D011799:Quinazolines; D000069476:Linagliptin